168196-87-0

Basic information

• Product Name: 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene
• Synonyms: 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene;2-(Benzyloxy)-5-bromo-o-xylene
• CAS NO: 168196-87-0
• Molecular Formula: C₁₅H₁₅BrO
• Molecular Weight: 291.183
• Mol File: 168196-87-0.mol

Chemical Properties

• Boiling Point: 365.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.306±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene(168196-87-0)
• EPA Substance Registry System: 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene(168196-87-0)

Safety Data

• Hazardous Substances Data: 168196-87-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be chemically modified and incorporated into complex drug molecules.
Used in Dye Industry:
In the dye industry, 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene is used as an intermediate for the production of various dyes, taking advantage of its chemical structure to create a range of colorants.
Used in Polymer Industry:
2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene is utilized as an intermediate in the synthesis of polymers, where its unique structure can contribute to the development of new materials with specific properties.
It is important to handle 2-(Benzyloxy)-5-bromo-1,3-dimethylbenzene with care and store it in a cool, dry place away from heat and direct sunlight to ensure safety and maintain its properties for use in these applications.

Upstream product

• 100-44-7 benzyl chloride 
• 2374-05-2 4-bromo-2,6-dimethyl-phenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 1044872-14-1 (4-benzyloxy-3,5-dimethylphenylethynyl)trimethylsilane 
• 910576-08-8 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 
• 910576-07-7 4-(2-oxo-1,2-dihydro-imidazo[4,5-c]quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910576-10-2 4-(2-oxo-1,2-dihydro-quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 910576-11-3 4-(2-oxo-1,2-dihydro-quinolin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 
• 910575-44-9 (R)-3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-hydroxy-propionic acid 
• 866087-23-2 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-methoxycarbonyl-ethyl ester 
• 866087-20-9 3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-oxo-propionic acid 
• 866087-22-1 (R)-3-(4-Benzyloxy-3,5-dimethyl-phenyl)-2-hydroxy-propionic acid methyl ester 
• 866087-24-3 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3,5-dimethyl-phenyl)-1-carboxy-ethyl ester 
• 924300-31-2 4-(benzyloxy)-3,5-dimethylbenzonitrile 
• 1146733-11-0 (4-benzyloxy-3,5-dimethyl-phenyl)-(6-chloro-pyrimidin-4-yl)-methanone 
• 1146732-60-6 1-{1-[6-(4-hydroxy-3,5-dimethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 
• 1146732-56-0 3-{1-[6-(4-hydroxy-3,5-dimethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one 

Relevant articles and documents

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Tyrosine analogues for probing proton-coupled electron transfer processes in peptides and proteins

A series of amino acids analogous to tyrosine, but differing in the physicochemical properties of the aryl alcohol side chain, have been prepared and characterized. These compounds are expected to be useful in understanding the relationships between structure, thermodynamics, and kinetics in long-range proton-coupled electron transfer processes in peptides and proteins. Systematic changes in the acidity, redox potential, and O-H bond strength of the tyrosine side chain could be induced upon substituting the phenol for pyridinol and pyrimidinol moieties. Further modulation was possible by introducing methyl and t-butyl substitution in the position ortho to the phenolic hydroxyl. The unnatural amino acids were prepared by Pd-catalyzed cross-coupling of the corresponding halogenated aryl alcohol protected as their benzyl ethers with an organozinc reagent derived from N-Boc L-serine carboxymethyl ester. Subsequent debenzylation by catalytic hydrogenation yielded the tyrosine analogues in good yield. Spectrophotometric titrations revealed a decrease in tyrosine pK a of ca. 1.5 log units per included nitrogen atom, along with a corresponding increase in the oxidation (peak) potentials of ca. 200 mV, respectively. All told, the six novel amino acids described here have phenol-like side chains with pKa's that span a range of 7.0 to greater than 10, and an oxidation (peak) potential range of greater than 600 mV at and around physiological pH. Radical equilibration EPR experiments were carried out to reveal that the O-H bond strengths increase systematically upon nitrogen incorporation (by ca. 0.5-1.0 kcal/mol), and radical stability and persistence increase systematically upon introduction of alkyl substitution in the ortho positions. The EPR spectra of the aryloxyl radicals derived from tyrosine and each of the analogues could be determined at room temperature, and each featured distinct spectral properties. The uniqueness of their spectra will be helpful in discerning one type of aryloxyl in the presence of other possible aryloxyl radicals in peptides and proteins with multiple tyrosine residues between which electrons and protons can be transferred.

Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions

The invention relates to CGRP-antagonists of general formula (I), wherein R1, R2, R3, R4 and R5 are defined in claim 1, to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures salts and salt hydrates thereof, in particular to 10 salts thereof, which are physiologically compatible with acids or inorganic or organic bases and to compounds of general formula (I), wherein one or several hydrogen atoms are substituted by deuterium. Drugs containing said compounds, the use thereof and a method for the production thereof are also disclosed.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Selected CGRP antagonists, process for their preparation as well as their use as medicaments

Heterocyclic esters (I), their tautomers, diastereomers, enantiomers, hydrates, mixtures and (hydrated) salts, particularly physiologically acceptable salts with (in)organic acids and bases, that are antagonists of calcitonin gene-related peptide (CGRP) a

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP-antagonists of general formula I wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS

The invention relates to novel CGRP antagonists of general formula (I), in which B, R1 and R2 are defined as cited in claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts, in addition to the hydrates of their salts, in particular their physiologically compatible salts, with inorganic or organic acids or bases. The invention also relates to medicaments containing said compounds, to their use and to a method for their production.

CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I) in which: R1, R2, R3, R4 and X are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts as well as the hydrates of the salts, in particular, their physiologically compatible salts with inorganic or organic acids and bases, and those compounds of general formula (I) in which one or more hydrogen atoms are replaced by deuterium. The invention also relates to medicaments containing these compounds, the use thereof, and to methods for producing them.

SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I), in which A, X, D, E, G, M, Q and R1 to R3 are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts having inorganic or organic acids, to medicaments containing these compounds, to their use, and to methods for the production thereof.